Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs

World Journal of Hepatology

Volumn 7, Issue 3, 2015, Pages 344-361

  de Nard, Francesca ^a   Todoerti, Monica ^a   Grosso, Vittorio ^a   Monti, Sara ^a   Breda, Silvia ^a   Rossi, Silvia ^a   Montecucco, Carlomaurizio ^a   Caporali, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Abatacept; Anti TNF; Biologics; Hepatitis B virus; Rheumatoid arthritis; Rituximab; Tocilizumab

Indexed keywords

EID: 84928946211     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i3.344     Document Type: Article

References (111)

1. Navarro-Millán I, Curtis JR. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 2013; 25: 384-390 [PMID: 23511719 DOI: 10.1097/BOR.0b013e32835fc62e]
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784 [PMID: 18512708 DOI:10.1002/art.2372]
3. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 Suppl 2: ii2-34 [DOI: 10.1136/annrheumdis-2013-20334]
4. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509 [PMID: 24161836 DOI: 10.1136/ annrheumdis-2013-204573]
5. Caporali R, Conti F, Alivernini S, Atzeni F, Seriolo B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011; 29: S7-S14 [PMID: 21906423]
6. Favalli EG, Caporali R, Sinigaglia L, Pipitone N, Miniati I, Montecucco C, Matucci-Cerinic M. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 2011; 29:S15-S27 [PMID: 21906424]
7. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol 2011; 24:269-274 [PMID: 21496415]
8. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, Galeazzi M. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010; 29: 517-524 [PMID: 20082236 DOI: 10.1007/s10067-009-1349-y]
9. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37 [PMID:16385520]
10. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581 [PMID: 15201414]
11. Nettelbladt O, Tengblad A, Hällgren R. High-dose corticosteroids during bleomycin-induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue. Eur Respir J 1990; 3: 421-428 [PMID: 1694778]
12. Emery P, Sebba A, Huizinga TW. Biologic and oral diseasemodifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1897-1904 [PMID: 23918035 DOI:10.1136/annrheumdis-2013-203485]
13. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-382 [PMID: 18635256 DOI: 10.1016/ S0140-6736(08)61000-4]
14. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72:64-71 [PMID: 22562973 DOI: 10.1136/annrheumdis-2011-201247]
15. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebocontrolled trials. Rheumatology (Oxford) 2003; 42: 6-13 [PMID:12509606]
16. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years:results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53 [PMID: 12528102]
17. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-2213 [PMID:8835550]
18. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39: 425-441 [PMID: 20223500 DOI: 10.1016/j.semarthrit.2009.12.002]
19. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70 Suppl 2: 266-271 [DOI:10.1136/ard.2010.132134]
20. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011; 162: 785-791 [PMID:21039421 DOI: 10.1111/j.1476-5381.2010.01099.x]
21. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis:systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-1308 [PMID: 22294630 DOI: 10.1136/ annrheumdis-2011-20049]
22. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343]
23. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14: 703-709 [PMID: 11185536]
24. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol 2012; 55: 296-302 [PMID: 22999800]
25. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51 Suppl 3: 581-592 [PIMD: 22999800]
26. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-396 [PMID: 20638020 DOI: 10.1016/ j.cld.2010.05.007]
27. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768 [PMID:11694101]
28. Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51:1531-1537 [PMID: 20087968 DOI: 10.1002/hep.23464]
29. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657 [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]
30. Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009; 51: 824-825 [PMID: 19664841 DOI: 10.1016/ j.jhep.2009.06.007]
31. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-163 [PMID: 22232374 DOI: 10.1128/CMR.00018-11]
32. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199 [PMID: 18722377 DOI:10.1053/j.gastro.2008.07.008]
33. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/ j.jhep.2012.02.010]
34. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720]
35. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim do Y, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51: 415-421 [PMID: 19902424 DOI: 10.1002/hep.23323]
36. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49:S156-S165 [PMID: 19399803 DOI: 10.1002/hep.22945]
37. Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013; 28: 31-37 [PMID: 23020594 DOI: 10.1111/j.1440-1746.2012.07280.x]
38. Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B, Le Guenno G, Mekinian A, Bernard-Chabert B, Costedoat-Chalumeau N, Descloux E, Michot JM, Radenne S, Rigolet A, Rivière S, Yvin JL, Thibault V, Thabut D, Pol S, Guillevin L, Mouthon L, Terrier B. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013; 65: 1504-1514 [PMID: 23436730 DOI:10.1002/acr.21990]
39. Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med 2011; 22: 572-575 [PMID: 22075282 DOI: 10.1016/ j.ejim.2011.09.00]
40. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-2219 [PMID: 22150039 DOI:10.1056/NEJMra1004965]
41. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25: 549-567 [PMID: 22137924 DOI:10.1016/j.berh.2011.10.004]
42. Tanaka T, Ogata A, Kishimoto T. Targeting of interleukin-6 for the treatment of rheumatoid arthritis: a review and update. Rheumatol Curr Res 2013; S4: 002
43. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6: e1 [PMID: 19143467 DOI: 10.1371/journal.pmed.006000]
44. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del Prete G, Fiaccadori F, Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-1194 [PMID: 8787682]
45. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgrad Med J 2013; 89: 294-304 [PMID:23596257 DOI: 10.1136/postgradmedj-2011-301073rep]
46. Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One 2014; 9: e103008 [PMID: 25047809 DOI:10.1371/journal.pone.0103008]
47. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-582 [PMID:9528902]
48. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963-970 [PMID: 17868872]
49. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R, Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98:144-150 [PMID: 12526950]
50. Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999; 115: 508-514 [PMID:10193426]
51. Daniels HM, Meager A, Eddleston AL, Alexander GJ, Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990; 335: 875-877 [PMID: 1969983]
52. Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H, Wakita T. Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem 2013; 288: 31715-31727 [PMID:24025329 DOI: 10.1074/jbc.M113.50112]
53. Rehermann B. Chronic infections with hepatotropic viruses:mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27: 152-160 [PMID: 17520515]
54. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949 [PMID: 17676045]
55. O'Quinn DB, Palmer MT, Lee YK, Weaver CT. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99:115-163 [PMID: 19117534 DOI: 10.1016/S0065-2776(08)00605-6]
56. Zhang JY, Zhang Z, Lin F, Zou ZS, Xu RN, Jin L, Fu JL, Shi F, Shi M, Wang HF, Wang FS. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91 [PMID: 19842207 DOI:10.1002/hep.23273]
57. Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2010; 30: 60-67 [PMID: 19756987 DOI: 10.1007/ s10875-009-9328-2]
58. Zhang F, Yao S, Yuan J, Zhang M, He Q, Yang G, Gao Z, Liu H, Chen X, Zhou B. Elevated IL-6 receptor expression on CD4+ T cells contributes to the increased Th17 responses in patients with chronic hepatitis B. Virol J 2011; 8: 270 [PMID: 21639870 DOI:10.1186/1743-422X-8-270]
59. Galun E, Nahor O, Eid A, Jurim O, Rose-John S, Blum HE, Nussbaum O, Ilan E, Daudi N, Shouval D, Reisner Y, Dagan S. Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo. Virology 2000; 270: 299-309 [PMID: 10792989]
60. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124: 2766-2770 [PMID:19267406 DOI: 10.1002/ijc.24281]
61. Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D, O'Brien SJ, Astemborski J, Thomas DL. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78: 11258-11262 [PMID: 15452244]
62. Jiang Z, Feng X, Zhang W, Gao F, Ling Q, Zhou L, Xie H, Chen Q, Zheng S. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 2007; 27: 1202-1208 [PMID: 17919231]
63. Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C. +49G & gt; A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010; 71:83-87 [PMID: 19778566 DOI: 10.1016/j.humimm.2009.09.353]
64. Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol 2009; 31: 345-358 [PMID:19533130 DOI: 10.1007/s00281-009-0169-0]
65. Mohamadkhani A, Naderi E, Sotoudeh M, Katoonizadeh A, Montazeri G, Poustchi H. Clinical feature of intrahepatic B-lymphocytes in chronic hepatitis B. Int J Inflam 2014; 2014: 896864 [PMID: 24579055 DOI: 10.1155/2014/896864]
66. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30: 1624-1625 [PMID:12858469]
67. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687 [PMID:12810441]
68. Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep 2013; 15: 319 [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1]
69. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217 [PMID: 18221983 DOI:10.1016/j.semarthrit.2007.10.011]
70. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179 [PMID: 19941642 DOI: 10.1186/ar2868]
71. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36:2416-2420 [PMID: 19797507 DOI: 10.3899/jrheum.081324]
72. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62:749-754 [PMID: 20535784 DOI: 10.1002/acr.20130]
73. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355 [PMID:20472596 DOI: 10.1136/ard.2009.127233]
74. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological diseasemodifying antirheumatic drugs. Mod Rheumatol 2011; 21: 621-627 [PMID: 21528424 DOI: 10.1007/s10165-011-0458-z]
75. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy:evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-564 [PMID: 21246383 DOI: 10.1007/ s00535-010-0367-5]
76. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-371 [PMID: 22033451 DOI: 10.1097/ MD.0b013e3182380a76]
77. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS. Kinetics of viral load and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumor necrosis factor therapy. Ann Rheum Dis 2011; 70:1719-1725
78. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing antitumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16: 527-531 [PMID: 24164839 DOI: 10.1111/1756-185X.12154]
79. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118-121 [PMID: 23111095]
80. Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ, Pang XF, Li ZG. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol 2014; 33: 119-123 [PMID: 24077913]
81. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 2014 Apr 4; Epub ahead of print [PMID:24698305 DOI: 10.1111/1756-185X.12359]
82. Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine 2014; 81: 478-484 [PMID:24561021 DOI: 10.1016/j.jbspin.2014.01.015]
83. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188 [PMID: 1983820]
84. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
85. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112 [PMID: 1054319]
86. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90:1219-1223 [PMID: 21520001 DOI: 10.1007/s00277-011-1241-0]
87. Lu S, Xu Y, Mu Q, Cao L, Chen J, Zhu Z, Lou Y, Meng H, Qian W, Tong H, Mai W, Huang J, Yu W, Zhao X, Jin J. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximabbased chemotherapy. Leuk Lymphoma 2014 Aug 19; Epub ahead of print [PMID: 25065698]
88. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31: 403-404 [PMID: 19830433 DOI:10.1007/s00296-009-1202-2]
89. Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 2012; 79: 100-101 [PMID:21944979 DOI: 10.1016/j.jbspin.2011.07.003]
90. Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia 2013; 17: 91-93 [PMID: 23935355]
91. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013; 72: 308-310 [PMID: 22930597 DOI: 10.1136/ annrheumdis-2012-202088]
92. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 2008; 47: 1838-1840 [PMID: 18854348 DOI: 10.1093/rheumatology/ken384]
93. Tsuboi H, Tsujii A, Nampei A, Yoshihara H, Kawano K, Takeuchi E, Shi K. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximabreactivated hepatitis B. Mod Rheumatol 2011; 21: 701-705 [PMID:21626075 DOI: 10.1007/s10165-011-0470-3]
94. Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Takasugi K. Successful tocilizumab treatment in a patient with adult-onset Still' s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011; 21: 215-218 [PMID: 20931272 DOI: 10.1007/s10165-010-0365-8]
95. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64: 1265-1268 [PMID: 22392695 DOI: 10.1002/acr.21654]
96. Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012; 56: 1420-1421 [PMID: 22127282 DOI: 10.1016/j.jhep.2011.10.011]
97. Bell A. The management and utilisation of operating departments. A review of the Bevan Report. NATNEWS 1990; 27: 5-7 [PMID:2377195 DOI: 10.1093/rheumatology/ket221]
98. De Nard F, Todoerti M, Grosso V, Rossi S, Caporali R, Montecucco C. Safety of the newer biological DMARDs, tocilizumab and abatacept, in rheumatoid arthritis patients with a history of HBV infection: a real life experience. Proceedings of the European League Against Rheumatism Congress; 2014 June 11-14; Paris, France. Ann Rheum Dis 2014; 73: 499 [DOI: 10.1136/annrheumdis-2014-eular.5021]
99. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142: 333-341 [PMID:15738452]
100. Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012; 11: 572-576 [PMID: 22037116 DOI: 10.1016/ j.autrev.2011.10.015]
101. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301 [PMID: 16206512]
102. Sturkenboom MC, Fautrel B, Rozenberg S, Bégaud B, Roullet E, Hainzlef O. Vaccinations against hepatitis B and lupus erythematosus. Pharmacoepidemiol Drug Safety 2000; 9: s71
103. Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8 [PMID:20708902 DOI: 10.1016/j.jaut.2010.07.003]
104. Maillefert JF, Sibilia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, Juvin R, Parchin-Geneste N, Piroth C, Wendling D, Kuntz JL, Tavernier C, Gaudin P. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 1999; 38: 978-983 [PMID: 10534549]
105. Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin Exp Rheumatol 2002; 20: 767-771 [PMID: 12508767]
106. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 623-625 [PMID: 12079904]
107. Ansemant T, Ornetti P, Garrot JF, Pascaud F, Tavernier C, Maillefert JF. Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patients seen by the rheumatologists of a defined area--brief report. Joint Bone Spine 2012; 79: 268-270 [PMID: 21733731 DOI: 10.1016/j.jbspin.2011.05.019]
108. Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, van der Burg M, Tak PP, Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037-1043 [PMID:22968102 DOI: 10.1136/annrheumdis-2011-201270]
109. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8: 766-770 [PMID: 2968945]
110. Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken) 2010; 62: 704-711 [PMID:20461789 DOI: 10.1002/acr.20209]
111. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-422 [PMID:21131643 DOI: 10.1136/ard.2010.137216]